Rudolf Napieralski1, Gabriele Schricker1, Gert Auer2, Michaela Aubele1, Jonathan Perkins3, Viktor Magdolen4, Kurt Ulm5, Moritz Hamann6, Axel Walch7, Wilko Weichert8, Marion Kiechle4, Olaf G Wilhelm1. 1. Therawis Diagnostics GmbH, Munich, Germany. 2. Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. 3. QIAGEN Manchester Ltd., Manchester, United Kingdom. 4. Department of Gynecology and Obstetrics and Comprehensive Cancer Center (CCCTUM), Klinikum Rechts der Isar, Technische Universität München, Munich, Germany. 5. Institute of Medical Informatics, Statistics and Epidemiology, Technische Universität München, Munich, Germany. 6. Department of Gynecology Rotkreuzklinikum München, Munich, Germany. 7. Research Unit Analytical Pathology, Helmholtz Zentrum München, Munich, Germany. 8. Institute of Pathology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Abstract
BACKGROUND: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer patients after anthracycline-based chemotherapy. To determine its prognostic versus predictive value, the impact of PITX2 DNA methylation on outcomes was studied in an untreated cohort vs. an anthracycline-treated triple-negative breast cancer (TNBC) cohort. MATERIAL AND METHODS: The percent DNA methylation ratio (PMR) of paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time PCR test. Patient samples of routinely collected archived formalin-fixed paraffin-embedded (FFPE) tissue and clinical data from 144 TNBC patients of 2 independent cohorts (i.e., 66 untreated patients and 78 patients treated with anthracycline-based chemotherapy) were analyzed. RESULTS: The risk of 5- and 10-year overall survival (OS) increased continuously with rising PITX2 DNA methylation in the anthracycline-treated population, but it increased only slightly during 10-year follow-up time in the untreated patient population. PITX2 DNA methylation with a PMR cutoff of 2 did not show significance for poor vs. good outcomes (OS) in the untreated patient cohort (HR = 1.55; p = 0.259). In contrast, the PITX2 PMR cutoff of 2 identified patients with poor (PMR >2) vs. good (PMR ≤2) outcomes (OS) with statistical significance in the anthracycline-treated cohort (HR = 3.96; p = 0.011). The results in the subgroup of patients who did receive anthracyclines only (no taxanes) confirmed this finding (HR = 5.71; p = 0.014). CONCLUSION: In this hypothesis-generating study PITX2 DNA methylation demonstrated predominantly predictive value in anthracycline treatment in TNBC patients. The risk of poor outcome (OS) correlates with increasing PITX2 DNA methylation.
BACKGROUND: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer patients after anthracycline-based chemotherapy. To determine its prognostic versus predictive value, the impact of PITX2 DNA methylation on outcomes was studied in an untreated cohort vs. an anthracycline-treated triple-negative breast cancer (TNBC) cohort. MATERIAL AND METHODS: The percent DNA methylation ratio (PMR) of paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time PCR test. Patient samples of routinely collected archived formalin-fixed paraffin-embedded (FFPE) tissue and clinical data from 144 TNBC patients of 2 independent cohorts (i.e., 66 untreated patients and 78 patients treated with anthracycline-based chemotherapy) were analyzed. RESULTS: The risk of 5- and 10-year overall survival (OS) increased continuously with rising PITX2 DNA methylation in the anthracycline-treated population, but it increased only slightly during 10-year follow-up time in the untreated patient population. PITX2 DNA methylation with a PMR cutoff of 2 did not show significance for poor vs. good outcomes (OS) in the untreated patient cohort (HR = 1.55; p = 0.259). In contrast, the PITX2 PMR cutoff of 2 identified patients with poor (PMR >2) vs. good (PMR ≤2) outcomes (OS) with statistical significance in the anthracycline-treated cohort (HR = 3.96; p = 0.011). The results in the subgroup of patients who did receive anthracyclines only (no taxanes) confirmed this finding (HR = 5.71; p = 0.014). CONCLUSION: In this hypothesis-generating study PITX2 DNA methylation demonstrated predominantly predictive value in anthracycline treatment in TNBC patients. The risk of poor outcome (OS) correlates with increasing PITX2 DNA methylation.
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Inko Nimmrich; Anieta M Sieuwerts; Marion E Meijer-van Gelder; Ina Schwope; Joan Bolt-de Vries; Nadia Harbeck; Thomas Koenig; Oliver Hartmann; Antje Kluth; Dimo Dietrich; Viktor Magdolen; Henk Portengen; Maxime P Look; Jan G M Klijn; Ralf Lesche; Manfred Schmitt; Sabine Maier; John A Foekens; John W M Martens Journal: Breast Cancer Res Treat Date: 2007-10-28 Impact factor: 4.872
Authors: I Vela; C Morrissey; X Zhang; S Chen; E Corey; G M Strutton; C C Nelson; D L Nicol; J A Clements; E M Gardiner Journal: Clin Exp Metastasis Date: 2013-10-26 Impact factor: 5.150
Authors: Sabine Maier; Inko Nimmrich; Thomas Koenig; Serenella Eppenberger-Castori; Inga Bohlmann; Angelo Paradiso; Frédérique Spyratos; Christoph Thomssen; Volkmar Mueller; Jörg Nährig; Francesco Schittulli; Ronald Kates; Ralf Lesche; Ina Schwope; Antje Kluth; Almuth Marx; John W M Martens; John A Foekens; Manfred Schmitt; Nadia Harbeck Journal: Eur J Cancer Date: 2007-06-29 Impact factor: 9.162
Authors: Sreeraj G Pillai; Nupur Dasgupta; Chidananda M Siddappa; Mark A Watson; Timothy Fleming; Kathryn Trinkaus; Rebecca Aft Journal: Breast Cancer Res Treat Date: 2015-09-23 Impact factor: 4.872
Authors: Michaela Aubele; Manfred Schmitt; Rudolf Napieralski; Stefan Paepke; Johannes Ettl; Magdalena Absmaier; Viktor Magdolen; John Martens; John A Foekens; Olaf G Wilhelm; Marion Kiechle Journal: Dis Markers Date: 2017-09-12 Impact factor: 3.434
Authors: Brian D Lehmann; Bojana Jovanović; Xi Chen; Monica V Estrada; Kimberly N Johnson; Yu Shyr; Harold L Moses; Melinda E Sanders; Jennifer A Pietenpol Journal: PLoS One Date: 2016-06-16 Impact factor: 3.240